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hel lenic- journal-of-cardiology/EditorialAtrial ﬁbrillation and hypertrophic cardiomyopathy: co-existing
conditions with additive risksHypertrophic cardiomyopathy (HCM) is deﬁned by the presence
of increased left ventricular wall thickness in the absence of
abnormal loading conditions and occurs in 1 in 500 of the general
population. HCM is associated with an increased risk of sudden car-
diac death and is probably the most common cause of sudden car-
diac death in young people. The underlying pathology of HCM
including disorganized myocardial architecture and replacement
ﬁbrosis represents arrhythmogenic substrate, causing lethal ven-
tricular tachyarrhythmias such as ventricular tachycardia and ven-
tricular ﬁbrillation.
Atrial ﬁbrillation (AF) is also a common arrhythmic event in pa-
tients with HCM that leads to disastrous outcomes including heart
failure, stroke, and death. The prevalence of AF in patients with
HCM has been reported to be 4- to 6-fold greater than that in the
general population. Although the true prevalence depends on the
study populations and diagnostic methods used for AF detection,
AF prevalence has been reported to range from 17% to 28% (Table
1).1e5 It is well recognized that AF is a major predictor of stroke,
and stroke prevention is the principal priority in AF management.6
Some cohort studies demonstrate that age, left atrial enlarge-
ment, and New York Heart Association (NYHA) class are associated
with an increased risk of developing AF, with heterogeneity among
studies. Patients with HCM are more likely to develop AF at a
younger age than the general population. In one cohort study, the
prevalence of AF in patients with HCM was 25% before age 50 years,
whereas in the general population, it was 0.5% at age 40-50 years.3
Left atrial enlargement, assessed by echocardiography as an increase
in left atrial diameter or volume, is also an independent predictor of
AF inpatientswithHCM, and the current ESC guidelines for theman-
agement of HCM recommend that patients in sinus rhythmwith left
atrial diameter 45 mm should undergo 48-h ambulatory ECG
monitoring every 6 to 12 months for AF detection (class IIA recom-
mendation).7 In particular, left atrial enlargement is one of the risk
factors for thromboembolism in HCMpatients even in sinus rhythm8
and should be carefully assessed with other risk factors as well.
However, these predictors for developing AF may be interpreted
as surrogate markers for disease progression of HCM. The underly-
ing pathophysiologies in HCM such as diastolic dysfunction and
mitral regurgitation due to left ventricular outﬂow tract obstruc-
tion cause left atrial pressure loading. Long-term accumulation of
myocardial remodeling, which represents left atrial enlargement
and replacement of atrial myocardial ﬁbrosis, results in the sub-
strate of developing AF and thrombus formation. Consequently,Peer review under responsibility of Hellenic Society of Cardiology.
https://doi.org/10.1016/j.hjc.2017.11.012
1109-9666/© 2017 Hellenic Society of Cardiology. Publishing services by Elsevier B.V. Thi
org/licenses/by-nc-nd/4.0/).the development of AF in patients with HCM may indicate that
the disease has already progressed to an end-stage phase.
In this issue of the journal, Zegkos et al sought to investigate the
prevalence and clinical features of AF in patients with HCM.9 In this
study, a substantial number of patients (23.4%) with HCM devel-
oped AF, in line with previous studies. Female gender, NYHA class,
and left atrial enlargement were independent predictors of AF
(odds ratio (OR) 2.2, 95% conﬁdence interval (CI) 1.3e3.5,
p ¼ 0.001, OR 1.9, 95% CI 1.1e3.5, p ¼ 0.02, OR 2.2, 95% CI 1.6e3.3,
p < 0.001, respectively). Moreover, they demonstrate the impact
of AF on mortality in patients with HCM, whereby AF was associ-
ated with an increased risk of overall mortality (hazard ratio 3.4,
95% CI 1.7e6.5). Subgroup analysis of 126 patients who underwent
cardiopulmonary exercise testing showed that AF was an indepen-
dent predictor of exercise intolerance in HCM patients, resulting in
reduced quality of life.
It is well recognized that thromboembolic events are also
frequently associated with HCM per se. A recent systematic review
reported that the prevalence and annual incidence of thromboem-
bolic events including stroke and peripheral embolism in patients
with HCM and AF were 2.4% and 5.0% per 100 patients, respec-
tively.10 Risk stratiﬁcations for thromboembolism, such as the
CHADS2 and CHA2DS2-VASc score, in patients with non-valvular
AF are well established, and oral anticoagulants are widely used
for thromboembolism prophylaxis.
However, these simple risk scores are not well validated in pa-
tients with HCM and AF. Guttmann et al reported that the
CHA2DS2-VASc score did not adequately risk stratify for thrombo-
embolism in HCM patients with AF who were not treated with
vitamin K antagonists (VKAs).11 Perhaps HCM patients with AF
tend to be younger and do not more frequently present with
vascular disease compared to other high-risk populations; howev-
er, this study categorized some HCM patients with a CHA2DS2-VASc
score of 0, despite HCM patients essentially having diastolic
dysfunction, as such patients (with so-called heart failure with pre-
served ejection fraction) would score 1 point for the C criterion on
the CHA2DS2-VASc score.6 Indeed, heart failure can be a powerful
driver of stroke risk even amongst young AF patients.12
In addition, non-vitamin K antagonist oral anticoagulants are
being increasingly established as alternatives to the VKAs for effec-
tive stroke prevention13,14; however, there are limited data to sup-
port the efﬁcacy and safety in patients with HCM and AF (as these
patients were excluded from the randomized trials), although some
small observational series of HCM have been reported.15s is an open access article under the CC BY-NC-ND license (http://creativecommons.
Table 1
Prevalence and predictors of AF and annual incidence rate of thromboembolism in patients with HCM
Year Study Number of
patients, n
Follow-up
period, years
Prevalence
of AF, n
Predictors of AF Incidence rate of thromboembolism
in AF patients, %
2001 Olivotto I, et al1 480 9.1 ± 6.4 107 (22%) age, LA enlargement, NYHA II 21.5
2002 Maron BJ, et al2 900 7 ± 7 192 (21%) n/a 23.4
2004 Losi MA, et al3 150 5.2 ± 2.9 20 (13%) age, LA enlargement, MR, LVOT obstruction n/a
2009 Kubo T, et al4 261 n/a 74 (28%) age, NYHA III, prior embolism/HF, LA/LV enlargement 20.2
2014 Siontis KC, et al5 3673 4.1 (median) 650 (18%) age, prior CAD/stroke, high BNP, LA enlargement,
non-obstructive LVOT, MR, LVEF<50%
n/a
AF; atrial ﬁbrillation, HCM; hypertrophic cardiomyopathy, LA; left atrial, NYHA; New York Heart Association, MR; mitral regurgitation, LVOT; left ventricular outﬂow tract, HF;
heart failure, LV; left ventricular, CAD; coronary artery disease, BNP; brain natriuretic peptide, LVEF; left ventricular ejection fraction, HT; hypertension.
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boembolism in HCM patients, these risk schemes are not directly
applicable to the HCM population. Current ESC guidelines for the
management of HCM patients also advocate that all patients with
AF should receive treatment with VKAs, irrespective of their risk
scores.7 Japanese cohort studies demonstrated that cardiomyopa-
thy (including both dilated and hypertrophic cardiomyopathy) is
independently associated with an increased risk of thromboem-
bolic events,16 and the coagulation system is activated in patients
with cardiomyopathy.17 Therefore, Japanese guidelines recommend
that anticoagulation should be considered in AF patients with car-
diomyopathy (class IIA recommendation).
In conclusion, AF has crucial impacts on morbidity and mortality
in patients with HCM. Many cohort studies demonstrate an intimate
relationship between AF and HCM, and AF in the HCM population
has some speciﬁc features that predispose to thromboembolism.
To prevent adverse outcomes in these patients, further efforts to
optimize clinical assessment and management pathways for pa-
tients with AF are needed in an integrated and holistic manner.
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